
Inscripta: MAD7 CRISPR enzyme widely adopted in first year of availability
BOULDER -- Inscripta , a gene-editing technology company, today announced MAD7, its proprietary CRISPR enzyme, has achieved wide adoption by academic, commercial, and government researchers in... Read More
Thursday December 20, 2018

Inscripta announces two major milestones
BOULDER -- Inscripta , a gene-editing technology company, announced two significant milestones. First, the USPTO granted Inscripta its first patent covering systems using MAD7, the... Read More
Friday July 13, 2018